FOCUSED ON SOLVING UNMET NEEDS IN OPHTHALMOLOGY

Addressing significant unmet medical needs for transformative topical therapy
image/svg+xml TABLEAU_OCULIS_04_21 2021-04-30T16:24:49+02:00 2021-04-30T16:24:49+02:00 2021-04-30T16:24:49+02:00 Adobe Illustrator 25.2 (Macintosh) 256 88 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAWAEAAwER AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAAAAAQFAwIGAQAHCAkKCwEAAgIDAQEBAQEAAAAAAAAA AQACAwQFBgcICQoLEAACAQMDAgQCBgcDBAIGAnMBAgMRBAAFIRIxQVEGE2EicYEUMpGhBxWxQiPB UtHhMxZi8CRygvElQzRTkqKyY3PCNUQnk6OzNhdUZHTD0uIIJoMJChgZhJRFRqS0VtNVKBry4/PE 1OT0ZXWFlaW1xdXl9WZ2hpamtsbW5vY3R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo+Ck5SVlpeYmZ qbnJ2en5KjpKWmp6ipqqusra6voRAAICAQIDBQUEBQYECAMDbQEAAhEDBCESMUEFURNhIgZxgZEy obHwFMHR4SNCFVJicvEzJDRDghaSUyWiY7LCB3PSNeJEgxdUkwgJChgZJjZFGidkdFU38qOzwygp 0+PzhJSktMTU5PRldYWVpbXF1eX1RlZmdoaWprbG1ub2R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo +DlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+v/aAAwDAQACEQMRAD8A9U4q7FXYq7FUr1jUfL/o XGm6lqFvb/WImjlikmjjfhIpU7MQRUHJCJPIMJTiOZY02j/l18Ij1qOFEpwjS/TipUsVIDM2686D 2AyXDLuR4sO8fNzRfl2Lf6sPMkMYEplLLqECycjQbvXltSn+2anw59x+TH8xj/nR+YUZvL35bzNz bXFrQKpGoRmirSgBJJoCoODhl3MvEh3j5pzo135M0kz/AFbW7dhcMGdZbyJwCK/ZHL4a8t/HAYS7 l8WHePmra7P5R1Wzt47/AFSCOHn9YtpEukiJZQ8XJWDbgVYbd8RCXck5I94SOTRPIDqaeYAGo3ps b+NuDsFHNeTH4vgrXDwy7keLDvHzWQ+X/wAvYzG7eYA8yRiIy/pBFLKCCR8LDYldx0x4Zdy+JDvH zRcdj5ASD0v03Gx9RJVla/QyK0Ssq0flUfbJ+ePDLuXxYd4+aFOgfl0V4HXV4VDOn16LizCu7ivx da77Y8Mu5fEh3j5rpNE/L54vSPmD4eLKT+kIySHPIj4iceGXcviw7x82QyeZPLEk8iNq1n6bxcSf rEXckEV5YPDl3FfFh3hIotJ/LuKL0k1tAq09I/pBaxhVCgIee3TDwy7l8WHePmpS6D+Xcob1NeVi xDFjfxV5KSQw32NT1H6seGXcviQ7x805sdS8oaZYXFvbazbyLIXk/e3iStyZQDQsxO9K/PAYS7l8 WHePmu1m+8k6xaLa32qWbwq6yhVuol+Ja8TUN2riIS7iviw7wlUOmeQYp0mTXx+7YOkR1BPTFFCc ePL7PEUph4Zdy+LDvHzTlvMHlaDTRbQ6tZlIo1jjX6zETRQAP2vbB4cu4r4sO8KOtXnkbWraO21D U7OSKN/VRRdRL8XBkrs3g5xEJdxXxYd4SyLTPISPIzeYBL6sckUiy6gjhlmWRWqC3X981Dh4Zdy+ LDvHzTq31vyrbafBY2uq2jJAkcECfWImYhAEUfa3O2Awl3J8WPeF+s+UdI1a6+uXPqx3YiECzwyN G6oOewI6V9VgfHIgs0FL+XmgzWklrPJdTQyyrORJOzEOnqU416f3zVx4lpONS0qy1MPa3iGSEelJ xBI+JGZl3HgRgVKh5B0YRMgnvAW51cXD8qSVqB7DkafPDarZvy90CaL0pWuXUhgeUzb8nZ2Y9ixL nc748S02v5f6KCSZ7xiSSxa4Ykgrw4luvGnauNqjNM8uWekNLLBPcyvOY1c3EzS7CUttX3kOJKpz gV2KuxVbL6npP6dPU4nhXpyptir4z1NtQbUbo6jz/SHqv9b9WvqeryPPlXvyzoI1W3J4jJxcR4vq 6sgW3/L0xJ/pNyHMRMvLkSJOD8eCrEA3xceQLADsxGU3kc0R01cz+PglutJ5XW1txpD3Elzsblp6 BfsD7KhRT4q13Pt4myHHfqaM4xUOC7SfLHGdirNzF5bk0byyPME1zBajTbkwtaBS5m/Sc1AwYMOP Dl/nsca5cUuHvH3OyAxmEPEJA4Zcv6yjJZ/lWlvyjvtTmnCt8BWOMFgvw7+nJSrfhh4svcEGGlr6 pfj4KdvZ/lkZJ/rF/qSRAJ9W9NI2ZtlL86ooH7QA+W+Jll7ggQ03WUvx8GhZflsWSuoX6ID+9PBW Yrv9gcFFTUdTtvudjjxZe4L4em/nS/HwVILL8rvWm9e/1L0RMBAUVORhpDUtWOleRm+gLt2KZZe4 KIaazcpfivL3oHXLXyNHp6to15ezahVC6XCIIqfF6gBAU914/Jq9RkoHJfqAprzQwCPoJMvNjuXO G7FXYq7FXYq7FXYq7FXYq7FX1L+U03muXyhbN5hSjigsXcn13t6fCZQe/gepHXxOl1Ijx+l67QHI cY4+f215szzHcxJfMo1A2zfUBOZxxP8Ao5AfiFk/mNDTsPGmx6YQqQf87Dcx/GdYRvQYqAIYjz9Q vUlT9orRQPo264VU7SfzWZF9f9KsPimC+nAoDVJSNj9FDsRuMdkOc+bHURtJqsU3GQsyRW5QFFZk Aav7RAHQ1x2VkmkWeowWonvb2a4a4FuRBOqKYTzLMvw0qfjAPywFKc4FdirsVad1jRnc0VAWY+w3 OKvmLzT+aMutavNdro2melUrC1xapNOUGy+pI3U0+gZucem4RVl5fP2hxyvhjXmLKoP8VEIf8OaP WRWeNfQtOTBFLOFXnyJUKeS0qOh6jI+j+dL7Wysv+pw+Q/WleqS6/pkcN1faPp8EVwaxD6vbNXYN TivJhSvf5dQcsiIy2BLTllkgLlCAvyCh/jSX/qzaR/0hR4fB85fNr/Of0If6V3+NJf8AqzaR/wBI UePg+cvmv5z+hD/Ssrlv9a1XS/LsOl6Fp15cyWFzO0H1WIhFS+mjPphiAB02HUnKOERMrJG/6HN4 5zhDhhEmj0/pIO3tvOtzIYoPKemyuFVyFs4D8L8+P7Xf0X+7JEwH8R+bERzE14cPkP1qh0/zyCgb ynpimTj6fK0tl5cg7LSrb1ETfdg4ofzingzf6nD5D9ajLD5yieJH8q6ZymZkjC2cDVZIzKw+FjuE Uk/KnXCDD+cfmxMcw/ycN/IfrVJ7LzvBMIZvKemJKeZCG0t6/ulDN0bwYEePbAJQ/nH5pMMw/wAn D5D9ax7fzmk6wP5U0wSuzxqhs4KlowS4+12C4bh/OPzXhzf6nD5D9a1I/Nr3xtF8s6SbgRvJw+rW 1OERUMwbnxP21779sfRV8UvtRWW68OF+4frVWsvPCStC3lLTVlUVZDZwVFQWFfi7gbDvg4ofzj80 8Gb/AFOHyH61P0fOH1eK4/wvpXpTRiaJvqttVozT4gOVduQ5eFd8Nw/nFHDmq/Dh8h+tbEnm+eC2 lTyvpnpXqhrZzaQLzVo2lBXkw/YQnE8H84/NYjKQCMcN/IfrVUtPOrwidfKml+kY/VDG0tx8FGPL dv8AIONw/nH5p4M3+pw+Q/Wl2satrejTrBqXl/SbeZwxVDaQMaKxRvslujKR9GThCMuUpfNpy5Z4 zUoQHwCXnznKRT9D6SPlZR5LwfOXzavzn9CH+lb/AMaS/wDVm0j/AKQo8fB85fNfzn9CH+ld/jSX /qzaR/0hR4+D5y+a/nP6EP8ASro/PE8cqSLo+kho2V1IsoxupricPnL5pGtIN8EP9K+lPJfnPSvN mjrqFieEi0S7tWNXikpXifEH9lu/4ZqMuIwNF6bTaiOWPFFP8qb0DqGofUi0v1ae6qEX07ZPUcV5 mpFRt8OKoJvNAoSmk6lIQnMgWxX9vhT42WrbcqeGGldF5qikdUGmaktWKlmtJFAAPHkSabY0qybz fDEoZtL1Mk1ARbVyx41rRQan7P6saVF2mrpqHqILS6tvRaElrqFoQ3KQiiFvtU4b08RjSpInmPzz Vg/lrlVY2XjcItCePqIa1BpUgNsNq4aCFf8AxD5tJVh5dYR+rwdTMhYRjlVx0rWgoOu+CglW0DzJ repXr295oFxpsKA8riZwV5hUPEDivIHmRyWo+HEhDISAQQRUHYg4Evmjzb5L8hWOvXdta+a4baNH NbV7e4nMJrvH6sKurceniO+bfFmyGO8XmdTpcEZkCdeVE18kL9W0n0/T/wCVgfu+Aj4ehqXHgoIC 04dACdslZ/mfcx9P+rH5SQVxpOi3HFZ/OdvNGlAgkg1FqKo4rQGA0oopkhKQ/g+5rlCB55b+Emv8 NeTv+pwtv+kK+/6pY+JP+b9oR4GH/VP9iXf4Z8nf9Thbf9IV9/1Sx8Sf837QvgYf9U/2JZBq2j+X Y9E8ucfNsVqsVpOsNwtte/vVN7M5YBI+ShX+GjdxXwyqMpcUvT93c5U8eMQhWStjvR33SlNN0FFC p57VVXlxAttQAHM8mpSP9o7nLOKX8z7mkRgP8t9knHTtBJUnz4pKV4n6tqO1etP3eC5fzPuWof6t 9klv6K8vcg3+Ok5ClD9W1Co4ii/7r7DYYeKX8z7l4Yf6r9km20zy+7Kzee0Zk3RjbagSOh2/d/5I x4pfzPuUxh/q32SWvpHlt6c/PEbUpStrqBpTp/uvHil/M+0IMYf6r9klxsNEYtG3nsFCCSTb6gQS xNRTh7n78Fy/mfcmof6sflJv9G6By5/47TnSnL6tqFaUp19Pww3L+Z9y1D/Vvsk5dN0BE9NPPaKl AvAW2oAUAoBT0+w2x4pfzPuURgNvG+yTnsNDIZj57V23NPq+oVJII7p3qcFy/mfctQ/1Y/KTYsdE FSPPo+Kpb/R9R3r1r+7xuX8z7lqH+rH5SUJtA8qzPzm86QSv05PaX7GnzMeSE5j+D7QwlixHnlv/ ADZKT+W/J4Ukeb7diOiiyvd/vjx8Sf8AN+0I8DD/AKp/sS3/AIZ8nf8AU4W3/SFff9UsfEn/ADft C+Bh/wBU/wBiU78t/lNZeZPWGi+ZrS7a3p6yehPGyhuh4yqhI9xleTVGH1Rb8PZ0cv0TBryTs/8A OOurpRpNYgKAjnxjetK70qcr/Pjucgdin+d9j2by55c0ry9pUWmaZF6VvFuzHd3c/ad27sf89s18 5mRsu6xYo448MeSZ5BsS/UtKsdUL217H6sICOFqR8VJFrUdxyxVBw+TNBijCLHKwCGL4ppTVT41b fx3774bVSTyF5bQqUhlHGMxbTSgFWDBqgNvy5mv9mNrSoPJPl4MSsMi1WReKzSKtJVZGHENx6Oe2 NqmqW0NrZQW0QpDAIo4wTWioVVdz8sCojFXYq7FVsqs8TqrcGZSFbwJHXFXx9rXlnXtI1Kexv7OV LiJiCeDFXFftq1KMp7HN9DJGQsF43LpskJEEFPF1bRfSVD5YcMsPBmABLuVYcqtGePEkUO5P7Vcq 4ZfznMGWFf3fT8dEt1vUtHu7CG3sdIawuomX1ZahuQVOJGyI1S3Wv661nCJBsm3Hz5ISiBGHCUn+ oX3/ACzy/wDAN/TLeId7j+FPuLf1C+/5Zpf+Ab+mPEO9fCn3Fmbva2ej+WpNS0h9Ti/Rt0iW9Xj4 SnUZmVyVBP2QdvfMbnKVGtx9zsRUYQ4o8Xpl/uln6X8q+oCfKD+nyjYp6ktQq/aUNT9rxOPDL+cn xMX+pFh5sL6u1tLT/Ub+mZPEO91vhS7i76hff8s0v/AN/THiHevhT7i76hff8s0v/AN/THiHevhT 7i76hff8s0v/AADf0x4h3r4U+4u+oX3/ACzy/wDAN/THiHevhT7i76hff8s0v/AN/THiHevhT7i7 6hff8s0v/AN/THiHevhT7i76hff8s8v/AADf0x4h3r4U+4u+oX3/ACzS/wDAN/THiHevhT7i76hf f8s0v/AN/THiHevhT7i76hff8s8v/AN/THiHevhT7i76hff8s0v/AADf0x4h3r4U+4s6/KDyt5ov PNUN9YvLp1rZEG8uytAUO5h4ts5fw7dfDMXVZIiNHe3YdnafIcnELiBz/U+krj+5b6P15qHplTFX Yql+pWEt7zhjupbNgFb1YTRukgA+VSD9GKoOHQNWSMLJrtzK3AozcIlq3Ztl2of86YbVSj8s6upU HzBdsojMbghKsWDAvWlQdxSnSnzxtVQeXtVBIXXbr0ysi8CqE/GrKDyI5VUtUb9sbVMba2ltbCG3 muHupI2UGeSnNv3gpWncDbAqMxV2KuxVbK/pxPJQtwUtxHU0FaYq+V9W/NXz1qF/LdDVp7RJGJjt rdzHGi12UBaVp4nfN3HTQAqnk8naOaRsGk+WX8xzCkn+LHIkiMyhZ5iAAjNR2KhVrw+Ek0bqDlP7 v+a5ojqKvxEr1vVfP+l2UF5L5ouphcFaJDdztx5IH3NeP4+42ycI45GuFx85z44iRmTfmUp/5WL5 7/6v17/yOf8Arln5eHcHH/PZv5xb/wCVi+e/+r9e/wDI5/64/l4dwX89m/nFl41vz3qul+X0sdfk tbiTT7i5uZZ7lohIU1CWEVberceIHsMx+CETKx1/Q58cmbJGHDKjRJ/01IdpvzLE8sP+LVLQkByL ySnIq7cQePZYifu8cP7r+b9i8OpuvEHz/YqW6fmpOnJfNQX4inF711YESGLcUrTkMScQ/h+xIhqj /GPn+xCavf8A5naXp7X0/mZ5I1KqUhu3kercewFNi3E79QRkoDFI1wteU6mEeIz+1j//ACsXz3/1 fr3/AJHP/XLfy8O4OH+ezfzi7/lYvnv/AKv17/yOf+uP5eHcF/PZv5xa/wCVh+eeXL9O3vKlK+s3 T78fy8O4L+ezfzi3/wArF89/9X69/wCRz/1x/Lw7gv57N/OLv+Vi+e/+r9e/8jn/AK4/l4dwX89m /nFo/mJ56IIOu3pB2I9Zv64/l4dwX89m/nFv/lYvnv8A6v17/wAjn/rj+Xh3Bfz2b+cXf8rF89/9 X69/5HP/AFx/Lw7gv57N/OLTfmH55YENrt6QeoMzf1x/Lw7gv57N/OLf/KxfPf8A1fr3/kc/9cfy 8O4L+ezfzizP8r/zZ8ww6/FpmsTT6paahIsas3KWaKQ7KyUqzL/Mv0j3x9Rpo8NjanO0HaE+Phn6 gXv1x/ct9H681b0KpirsVQOo3V5bB5LS0N7LRf3IcR7Uc15MD4U+nFUDHrmtulToUyMULhWliHxC tFNCeop9P34aVTi8wa+xAfy9MlULV9aM0ahKoenWm57V740qouu65Xi+hTB+LmqyxslVUlRyND8R AHTvjSphb3FxcafDNc25tJ3ZOduzBip9QCnIbGuBUVzb/fbf8L/XFXc2/wB9t/wv9cVdzb/fbf8A C/1xV3Nv99t/wv8AXFXkPmf8tfytl1ieR9Sl0y4di09pBJE0auTU0Vg5Tf8AZr8gMzcepyAcrdXm 7NwyldkJT/yrD8rf+piuf+Ch/wCaMs/N5O5q/krD/OP2fqQ5/Lb8sQ9P8SXNAenpr0+fHD+ayfzU fyVh/nH8fBEf8qw/K3/qYrn/AIKH/mjB+bydyf5Kw/zj9n6nf8qw/K3/AKmK5/4KH/mjH83k7l/k rD/OP2fqTLU/y9/LqfTNIgn1y4jgtIJY7SQGKsiNcSSMx+HtI7L9GQjqZgk1zbZ9nYjGIMjUfd3+ 5Lf+VYflb/1MVz/wUP8AzRk/zeTuav5Kw/zj9n6nf8qw/K3/AKmK5/4KH/mjH83k7l/krD/OP2fq d/yrD8rf+piuf+Ch/wCaMfzeTuX+SsP84/Z+p3/KsPyt/wCpiuf+Ch/5ox/N5O5f5Kw/zj9n6nf8 qw/K3/qYrn/gof8AmjH83k7l/krD/OP2fqWf8qy/K/1Cv+Ibnhxry5Q9a9PsY/m8ncv8lYf5x+z9 S/8A5Vh+Vv8A1MVz/wAFD/zRj+bydy/yVh/nH7P1IvTfyZ/L/U5XisNbu7iSMcnRGgqFJpWhXInW THMBI7JxHlKX2fqR8v8Azj35aSJ3+vX54qTSsHYV/lwfn5dwT/I+Lvl9n6l3/QvHln/lvv8A74P+ acfz8u4L/I+Lvl9n6nf9C8eWf+W+/wDvg/5px/Py7gv8j4u+X2fqU5/+cfPLUULyC+vyVFaVg/5p x/Py7gv8j4u+X2fqVP8AoXjyz/y33/3wf804/n5dwX+R8XfL7P1Mm8k/lh5f8pXEt3apNd3sg4pc 3BjLRpTdU48QK9z1ynNqZT2PJy9NoYYdxufNltw7ei37tu38vj88x3MVebf77b/hf64q7m3++2/4 X+uKqayN9Ycem32E/l8W98VVObf77b/hf64q7m3++2/4X+uKu5t/vtv+F/riqnMxKKChA5puafzj 3xVYuqaY9ublbyBrYKXM4kQoFHU8q0pvirUWq6XKFaK8gkVq8SsiEGmxpQ4q4atpbSCIXkBkapVB InI8WZWoK9mRgfcHFVb1Uljf0JFZqEBlIND26Yq+db+0vLS8mt71Gjuo2IlV/tcvGp616175ng3y cAgg7s0tb31bcK+oaaihI4iJAVJXioJHCau4JBJodtwOuUkeRbwfMLpJ3YNHJrdhJDB6cTq55eoi p6fIkSlyVVy1FO5+7GvJb8wkesafa3L3epSanbtdPWVreOhq5CEqpMj1Hxkdf2Tk4npTCQB3tjuW NTJvW0eKw0NtVgkntzZy8UiPFg/16Q16rtxDD6cr3s027ULQ4vfJzR0fT7hZCKExybAlKVAZm/a+ L8MNS70XHuU4LnymqETWlxI3KQghgvwmvpj7Z3G39uJElBiqi88mCpNhcHqAOe3VqH7fuu3t18Wp JuPclurS6VJcK2mQyQW/H4klPJuXJj1q3RSBko31YSrogsLF2KuxVOvJ9lrd1rtv+hyY7qI8zMfs Ig2Yv/k70p36ZCZAG7PGDez3e4qLSTkakRtyIFBXj2FTmE5qrirsVUL40tJSey4qr4q7FVO5NIWP y/XiqpirsVS7VNPkvw9vHeT2TARv61uwV9i+1SCKfRiFQR8s33qJINcveSSB2BYcWSgDIVAA33p4 E9NhhtXL5ZvQ3Jtcv2NKD4kFCCSDQLTvjat2/lu9ilhdtbvZViZXeN2Wj8WDFWoAaGn3bdMbVOp/ sD/XT/iQwKkqeRvKcbFo9Nijb0xEGTkpCgIBxII4sPSX4hv77nDZWlreQvKLc+WnKTIAHbnJUgHk N+VeuNlaak8geUJLeK2fTwYII/RiQSSgCPk78dn3+KVjv/THiKKRGgeV9D8t2kq6bAYw6qZ3LFnf 0weNa7bA9sSbV5Lq3n/zBqF283qJFDU+jD6UThF7Dk6sTmXHGA4pykpol+7xKy6uA7RowVrOMfG4 GwIiOwY9cjXkzvzQzSIeB+tsk78eXK2jKpKyFijH0h+18I2woQmoa55gguZRC7NaKT6Uz20I5IP2 q+nTvhEQxlKQQX+LNd/3+n/IiD/mjDwBj4hZB9e80ahY6Slg0bztZzTzAxwDZLqRKjmtOlOmQqIJ tsuRApSEPn5pFjVY2LCoPpW9KbdSU264fSvrbS38+vF6oMPD1XgqVtftoxQj7P8AMuxwelfWugtP zCmiSREj4yCq8o7ZTugfcFdtj39/DG4LU1gh8+Gn90CRWhS2B+wH7r4Nh9K+tLdS1vzRp17JZ3cs aXEXEuoit2HxKGWhVCDUMMkIxLAzkDSF/wAV67WvrpXp/cw/80Y8AR4hb/xZrv8Av9P+REH/ADRj wBfEKdeVPzBvdP1OuolZrKcBJuEaI60J4uOCrWlemRniBGzOGUg7vYJmDWkjLurRkj5EZiOUq4q7 FVG8/wB5ZPliqtirsVU7j+5b6P14qqYq7FUv1TUv0cr3Btbi7FI19K0j9WQVLnlxqNhTFUEfNiCS NTpWoqryCL1Gt+KgkDjWrbAlgKnv8sNK4eawWoNH1OgUMWNsQO+27CpFOgxpW7fzUJ5YYxpOpRtM yqGltmRVDMBydqkKADyP9caVOZ/sD/XT/iQwKvxV2KuxV2KsD1L8o9KubuSe1u3tI5CW9DgHVSey mq0GXDMWk4QUxt/JepW8fpxauFUlWY/VkJLLQVqW7hQD2wHIO5mIHvXN5T14vI662imRgxP1NTTj QrSsh+yVB+YwcY7kcJ71C48hXc9tJbyaqPSkXgwFuBRaItAOdNvSFMIyeSmHmlP/ACpu2/6uj/8A Ikf815Px/Jh4A70Xd/lVBcWljbHUXUWUTxBvSB5c5Xlr9rb+8pkRm8knChP+VN2//V1f/kSP+a8P j+SPAHe7/lTdt/1dH/5Ej/mvD4/kvgDvd/ypu2/6uj/8iR/zXj4/kvgDvcPybtx01V/+RI/5rweP 5L4A73f8qbtv+ro//Ikf814fH8l8Ad7X/Km4OVP0o/GnX0h1/wCDweP5L4A72/8AlTdt/wBXR/8A kSP+a8Pj+S+AO9M/L35Y6XpOoLezzm+eOhgR0Cqr/wAxFWqR28MhLMSKZRxAG2YyqWidR1ZSB9Iy ptXYq7FVk6M8LovUjbFV+KuxVbKpaMqOp/riq7FXYqtCn1WbsVUD6Cf64quxV2KuxVZMpZAAKnkp +gMCcVX4q7FXYq7FWOX2t+Zori6SHTAYouXoSkSPzKkhVogP2lHPl0H2TvvhpVaPVvMT3F0h0sxQ RRs0DuQWeT0+SrxQsv2ttm9vHFUPN5n16KNJBoE8nqRo/BWPJGatVb4O1P7OlWlXL5k15vXb9ATq IYyyoXHKR/WWMBSFp9glz8saV1/r3mWKJJLXRjK5jZ3g5EtUMKDnRVrxJ27nbYb40rc+veY7aCB3 0Rrh5lYskMhqhFSAw4tTsOvfGlWSeYvMqBwNBdyB8EiymhJO3wlA3Slff78aVqPzbqz6gbH9BzLL xJVmchSQHbdjHxApHStftEAVG+NK0PMvmYwNP/h6VApakDSAykKP8kFdz0IJ27Y0qpc635kWedIt L4QoKwyuHep4EhSIwTuR9odOnXGlb/TnmM3zQjSWSD0y8cjgkswgZ+JKF1U+qFWhO9etRTGlWS+Z 9eQQuvl+eRZYkdlDGsbmVkZW+D+QB+nT6MaVdD5k1+RpeWgTRJHEzryfd3EqIqii/wAjM56nag3x pV03mDzAogEehyF5WPqKZNkWi0qwTavPfwoevXGlUdO816xeLI/6DnjRRNw5llPKHorVT9vtSv0n bGlVG8w+Y1aNBoTvJxVpWEhCfEhaisU6jYEU67e+NK3P5h8wC9uLeDQ5DBCxVLp3PGQAkAqgWtDQ d8aVDyebPMMYjZvL03EkCQhzvVajiOHUsQBy+mh2xpV+p+add01JJJdDkniE7xRvA7t8AYKsjgRs aNy7D6NsaVuDzP5jlVOflyaJnDEhpthx7EiPqe3+3RpXN5j8yGVoE0R+bJEyTkv6atJCrsrAqvLj ISuxHvTGlaufNOt2llNcT6HM7xOU9OMncKhJaoD1VnX4SOxHcEY0q7/E3mAw+qmgSsGcIiFyrULU DkFPs037UxpWtS1nzdAFks9LS5SUUCUZWjPpxNVuRXkOTuvRSOPzo0FTnSb29u4ZWu7RrSWKVogr EnmqgHmNhsa+/wAzgKo3FXYq7FX/2Q== xmp.iid:623ef449-997f-42b0-9e91-54d3b938107d xmp.did:623ef449-997f-42b0-9e91-54d3b938107d uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:01befc7a-5c15-4536-b001-6c4a0fde79a9 xmp.did:01befc7a-5c15-4536-b001-6c4a0fde79a9 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf saved xmp.iid:44433185-2184-4731-93c4-278700048922 2019-11-26T15:11:19+01:00 Adobe Illustrator CC 2017 (Macintosh) / saved xmp.iid:623ef449-997f-42b0-9e91-54d3b938107d 2021-04-30T16:24:49+02:00 Adobe Illustrator 25.2 (Macintosh) / Print AIRobin False True 1 40.461980 14.879488 Centimeters Cyan Magenta Yellow Black Groupe de nuances par défaut 0 Blanc CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Noir CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 Rouge CMJN CMYK PROCESS 0.000000 100.000000 100.000000 0.000000 Jaune CMJN CMYK PROCESS 0.000000 0.000000 100.000000 0.000000 Vert CMJN CMYK PROCESS 100.000000 0.000000 100.000000 0.000000 Cyan CMJN CMYK PROCESS 100.000000 0.000000 0.000000 0.000000 Bleu CMJN CMYK PROCESS 100.000000 100.000000 0.000000 0.000000 Magenta CMJN CMYK PROCESS 0.000000 100.000000 0.000000 0.000000 C=15 M=100 J=90 N=10 CMYK PROCESS 15.000000 100.000000 90.000000 10.000000 C=0 M=90 J=85 N=0 CMYK PROCESS 0.000000 90.000000 85.000000 0.000000 C=0 M=80 J=95 N=0 CMYK PROCESS 0.000000 80.000000 95.000000 0.000000 C=0 M=50 J=100 N=0 CMYK PROCESS 0.000000 50.000000 100.000000 0.000000 C=0 M=35 J=85 N=0 CMYK PROCESS 0.000000 35.000000 85.000000 0.000000 C=5 M=0 J=90 N=0 CMYK PROCESS 5.000000 0.000000 90.000000 0.000000 C=20 M=0 J=100 N=0 CMYK PROCESS 20.000000 0.000000 100.000000 0.000000 C=50 M=0 J=100 N=0 CMYK PROCESS 50.000000 0.000000 100.000000 0.000000 C=75 M=0 J=100 N=0 CMYK PROCESS 75.000000 0.000000 100.000000 0.000000 C=85 M=10 J=100 N=10 CMYK PROCESS 85.000000 10.000000 100.000000 10.000000 C=90 M=30 J=95 N=30 CMYK PROCESS 90.000000 30.000000 95.000000 30.000000 C=75 M=0 J=75 N=0 CMYK PROCESS 75.000000 0.000000 75.000000 0.000000 C=80 M=10 J=45 N=0 CMYK PROCESS 80.000000 10.000000 45.000000 0.000000 C=70 M=15 J=0 N=0 CMYK PROCESS 70.000000 15.000000 0.000000 0.000000 C=85 M=50 J=0 N=0 CMYK PROCESS 85.000000 50.000000 0.000000 0.000000 C=100 M=95 J=5 N=0 CMYK PROCESS 100.000000 95.000000 5.000000 0.000000 C=100 M=100 J=25 N=25 CMYK PROCESS 100.000000 100.000000 25.000000 25.000000 C=75 M=100 J=0 N=0 CMYK PROCESS 75.000000 100.000000 0.000000 0.000000 C=50 M=100 J=0 N=0 CMYK PROCESS 50.000000 100.000000 0.000000 0.000000 C=35 M=100 J=35 N=10 CMYK PROCESS 35.000000 100.000000 35.000000 10.000000 C=10 M=100 J=50 N=0 CMYK PROCESS 10.000000 100.000000 50.000000 0.000000 C=0 M=95 J=20 N=0 CMYK PROCESS 0.000000 95.000000 20.000000 0.000000 C=25 M=25 J=40 N=0 CMYK PROCESS 25.000000 25.000000 40.000000 0.000000 C=40 M=45 J=50 N=5 CMYK PROCESS 40.000000 45.000000 50.000000 5.000000 C=50 M=50 J=60 N=25 CMYK PROCESS 50.000000 50.000000 60.000000 25.000000 C=55 M=60 J=65 N=40 CMYK PROCESS 55.000000 60.000000 65.000000 40.000000 C=25 M=40 J=65 N=0 CMYK PROCESS 25.000000 40.000000 65.000000 0.000000 C=30 M=50 J=75 N=10 CMYK PROCESS 30.000000 50.000000 75.000000 10.000000 C=35 M=60 J=80 N=25 CMYK PROCESS 35.000000 60.000000 80.000000 25.000000 C=40 M=65 J=90 N=35 CMYK PROCESS 40.000000 65.000000 90.000000 35.000000 C=40 M=70 J=100 N=50 CMYK PROCESS 40.000000 70.000000 100.000000 50.000000 C=50 M=70 J=80 N=70 CMYK PROCESS 50.000000 70.000000 80.000000 70.000000 Gris 1 C=0 M=0 J=0 N=100 CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 C=0 M=0 J=0 N=90 CMYK PROCESS 0.000000 0.000000 0.000000 89.999400 C=0 M=0 J=0 N=80 CMYK PROCESS 0.000000 0.000000 0.000000 79.998800 C=0 M=0 J=0 N=70 CMYK PROCESS 0.000000 0.000000 0.000000 69.999700 C=0 M=0 J=0 N=60 CMYK PROCESS 0.000000 0.000000 0.000000 59.999100 C=0 M=0 J=0 N=50 CMYK PROCESS 0.000000 0.000000 0.000000 50.000000 C=0 M=0 J=0 N=40 CMYK PROCESS 0.000000 0.000000 0.000000 39.999400 C=0 M=0 J=0 N=30 CMYK PROCESS 0.000000 0.000000 0.000000 29.998800 C=0 M=0 J=0 N=20 CMYK PROCESS 0.000000 0.000000 0.000000 19.999700 C=0 M=0 J=0 N=10 CMYK PROCESS 0.000000 0.000000 0.000000 9.999100 C=0 M=0 J=0 N=5 CMYK PROCESS 0.000000 0.000000 0.000000 4.998800 Couleurs vives 1 C=0 M=100 J=100 N=0 CMYK PROCESS 0.000000 100.000000 100.000000 0.000000 C=0 M=75 J=100 N=0 CMYK PROCESS 0.000000 75.000000 100.000000 0.000000 C=0 M=10 J=95 N=0 CMYK PROCESS 0.000000 10.000000 95.000000 0.000000 C=85 M=10 J=100 N=0 CMYK PROCESS 85.000000 10.000000 100.000000 0.000000 C=100 M=90 J=0 N=0 CMYK PROCESS 100.000000 90.000000 0.000000 0.000000 C=60 M=90 J=0 N=0 CMYK PROCESS 60.000000 90.000000 0.003100 0.003100 Adobe PDF library 15.00

OCS-01 phase 2 study results in DME

 

Interviews with Dr. Pravin U. Dugel

Dr. Pravin U. Dugel
DME Treatments and Challenges

Dr. Pravin U. Dugel
OCS-01 Phase 2 Study Results

Dr. Pravin U. Dugel
OCS-01 Phase 2 Study : Case Studies

OCS-01 is an investigational drug and has not received regulatory approval for commercial use in any country. Some of the statements in the video reflect Dr. Pravin U. Dugel’s perception of the results from the phase 2 clinical trial in DME and some of the forward-looking statements reflect his opinion on potential future use of OCS-01 based on his clinical experience.

OCS-02 Phase 2 Proof-of-concept Study Results in Dry Eye Disease

and Acute Anterior Uveitis

Presented on May 7th at ARVO 2021

Dr. Anat Galor
OCS-02 AAU Presentation at ARVO

Dr. Victor Perez
OCS-02 DED Presentation at ARVO

OCS-02 is an investigational drug and has not received regulatory approval for commercial use in any country. The video presentations may contain some statements that reflect the presenter’s perception of the clinical trial results and some forward-looking statements that reflect the presenter’s opinion on potential future use of OCS-02 based on clinical experience.

OCS-01: A potential paradigm
shift in DME treatment

One of our most advanced product candidates, OCS-01, has successfully completed a Phase 2 trial in DME (DX-211) with 144 patients providing the first proof-of-concept for a topical drug effect on a chronic retinal disease. If approved in DME, it has the potential to provide a new and potentially the FIRST non-invasive option for patients.

 

OCS-01 also successfully completed another Phase 2 trial in Inflammation and Pain following cataract surgery. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.

 

OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.

OCS-01: A potential treatment
for Post-cataract Surgery Inflammation

 

OCS-01 successfully completed a Phase 2 trial in Inflammation and Pain following cataract surgery (SKYGGN trial) with 153 patients providing the first proof-of-concept of a once daily topical steroid. A long-acting topical solution, such as OCS-01, has the potential of reducing the burden of administration given that patients undergoing cataract surgery are usually on several medications daily.

 

OCS-01 also successfully completed another Phase 2 trial in DME. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.

 

OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.

OCS-02: THE POTENTIAL OF
topical anti-TNF alpha
therapy for ophthalmic
indications

The compound, named OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including two controlled studies under IND. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye including Uveitis and Dry Eye Disease.